Related Experiment Video

Updated: Mar 29, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.4K

Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders

Jun Zhang1, Yang Li1

  • 1Amgen Inc. , South San Francisco, CA , USA.

Frontiers in Endocrinology
|November 24, 2015
PubMed

Insights

Fibroblast growth factor (FGF) 21 is a key metabolic regulator. Therapies targeting FGF21 show promise for type 2 diabetes and obesity, but challenges remain in development.

Area of Science:

  • Endocrinology
  • Metabolic diseases
  • Molecular biology

Background:

  • Fibroblast growth factor (FGF) 21 is an endocrine hormone.
  • FGF21 levels are altered in metabolic conditions like type 2 diabetes, obesity, and cardiovascular diseases.
  • FGF21 regulates diverse metabolic parameters.

Purpose of the Study:

  • To review therapeutic strategies targeting FGF21 for metabolic disorders.
  • To highlight the challenges associated with FGF21-based drug development.

Main Methods:

  • Literature review of FGF21 research.
  • Analysis of therapeutic approaches targeting FGF21 and its receptors.
  • Discussion of developmental challenges.

Main Results:

  • FGF21 plays a significant role in metabolic regulation.
  • Various therapeutic strategies targeting the FGF21 pathway are under investigation.
  • Developmental hurdles exist for FGF21-based therapies.

Conclusions:

  • FGF21-targeted therapies offer potential for metabolic diseases.
  • Overcoming developmental challenges is crucial for clinical success.
Keywords:
FGF19FGF21FGFR1antibodybeta-Klothodiabetesobesitytherapy

More Related Videos

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

1.8K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.3K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Introduction to Fibroblasts01:09

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
4.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
640